Subcategories:

Sort by:

select Language:



Gap analysis: which diseases have treatments on the market or promise in the pipeline?

Access to Medicine Foundation, (2018)


When pharmaceutical companies take action to improve access to medicine, it has the largest impact on their own products. The Access to Medicine Index has identified which products those are – as well as future products still in development – for 20 of the world’s largest research-based pharmaceutical companies
https://accesstomedicinefoundation.org/access-to-m...


Access to Medicines 2018. Fact Sheet

Access to Medicine Foundation, (2018)


The 2018 Access to Medicine Index finds that the pharmaceutical industry continues to mature in its approach to access to medicine, with models for good practice in areas such as access planning and licensing. GSK retains its No. 1 position, as Novartis moves up into 2nd. Takeda rises furthest in 2018, jumping ten places to fifth Download the full report from (Large File 22 MB) https://accesstomedicinefoundation.org/media/uploads/downloads/5c8bc9ceb714b_Access%20to%20Medicine%20Index%202018.pdf
https://accesstomedicinefoundation.org/media/uploa...


Medicines Patents, Access and Innovation

Brot für die Welt, (2016)


The growing challenges for people in low and middle-income countries to access new medicines. Analysis 58
https://www.brot-fuer-die-welt.de/fileadmin/mediap...


Medicines Catalog August 2018

Global Drug Facility, Eds.: World Health Organization WHO, Stop TB, (2018)


The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
http://stoptb.org/assets/documents/gdf/Medicines_C...


UPDATING NATIONAL ESSENTIAL MEDICINE LISTS: A STEP-BY-STEP ADVOCACY GUIDE

Eds.: Management Sciences for Health (MSH), (2016)


This guide provides national stakeholders and advocates with information and guidance to update the national essential medicines list to include a new commodity, a new indication, or a new formulation based on the available evidence and based on country need and disease burden. While the actors, timeline, and process may vary from country to country, this guide presents the broad steps involved in revising an EML for any health commodity. Additional resources and a glossary are included to provide supplemental information and to clarify key terms.
https://www.msh.org/resources/updating-national-es...


IMPROVING MEDICINES ACCESS AND USE FOR CHILD HEALTH: A GUIDE TO DEVELOPING INTERVENTIONS

Ross-Degnan, D., Vialle-Valentin, C., and Briggs, J. , Eds.: USAID, SIAPS (Systems for Improved Access to Pharmaceuticals and Services), (2015)


Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. This manual provides a framework to identify problems and design interventions to improve access to and use of medicines for children. It is a resource for both health policy makers and health system managers and presents a structured approach to the steps introduced in the framework in the context of child health.
https://www.msh.org/sites/msh.org/files/ch_interve...


Guidelines for the production, control and regulation of snake antivenom immunoglobulins

[World Health Organization (WHO)], (2017)


Replacement of Annex 2 of WHO Technical Report Series, No. 964

http://www.who.int/bloodproducts/AntivenomGLrevWHO...


World Health Organization Model List of Essential In Vitro Diagnostics First edition (2018)

World Health Organization (WHO), (2018)


The World Health Organization (WHO) published the first edition of the Model List of Essential In Vitro Diagnostics (EDL) in May 2018, in recognition that IVDs are an essential component to advance universal health coverage, address health emergencies, and promote healthier populations, which are the three strategic priorities of the WHO Thirteenth General Programme of Work (2019–2023)(GPW). The EDL is also intended to complement the WHO Model List of Essential Medicines (EML) and inhance its impact.
http://www.who.int/medical_devices/diagnostics/WHO...


MSF Essential Drugs - Practical Guidelines. Arabic Version

Medécins sans Frontières, (2016)


This guide is not a dictionary of pharmacological agents. It is a practical manual intended for health professionals, physicians, pharmacists, nurses and health auxiliaries invoved in curative care and drug management. We have tried to provide simple, practical solutions to the questions and problems faced by field medical staff, using the accumulated field experience of Médecins Sans Frontières, the recommendations of reference organizations such as the World Health Organization (WHO) and specialized documentation in each field.
http://www.refbooks.msf.org/msf_docs/ar/ed_ar.pdf


45 hits